UV light gives Schneck Medical Center another layer to infection prevention

Schneck Medical Center is using ultraviolet (UV) light to help offer its patients the cleanest environment possible. The Clorox Healthcare Optimum-UV System helps the provider take another step toward a germ-free medical center.

The Clorox system uses the highest form of ultraviolet light, UV-C, to kill germs that can cause infections. The UV light alters the germs genetic makeup, rendering them harmless and unable to multiply. Germs like MRSA and C. diff spores are effected within just five minutes under the UV light.

"Cleaning and disinfection plays a crucial role in infection prevention and with germs such as C. diff able to survive on surfaces for months at a time, we felt it was important to implement even more comprehensive cleaning procedures as part of our daily cleaning practices," said Anita Reecer, RN, BSN, an infection preventionist. "We've found that the Clorox Healthcare Optimum-UV System provides an effective, high-quality and easy to use solution that has helped achieve reductions to our already low infection rates."

Schneck uses the system to reduce infection rates in the surgical suites, inpatient and outpatient areas.

"Patient safety is a top priority at Schneck," said Reecer. "We chose a UV device as an added measure to help us prevent healthcare-associated infections and ensure the safest possible environment of care for our patients, staff, and visitors. The device is able to treat areas that are difficult to clean manually, leaving no crevice unturned."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.